Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

  • ID: 4370204
  • Report
  • Region: Global
  • 136 Pages
  • GBI Research
1 of 5
Introduction to Dermatology, Including Disease Epidemiology, Symptoms, Etiology, Pathophysiology, Co-Morbidities and Complications. Disease Classification and Methods of Diagnosis are Also Provided

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Astellas Pharma
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Summary

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient’s quality of life. For example, patients with severe atopic dermatitis (the most common form of eczema) may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, most dermatological conditions are visible, and as such can have a profound impact on patient confidence.

There are 850 products in the dermatology pipeline with a disclosed stage of development, but the majority of these drugs are at an early stage of development. Some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage. However, 32% of the pipeline is in clinical development, but only 3% are in the Pre-registration stage and less than half are novel.

Four drugs that were approved for psoriasis are Cosentyx, Otezla, Eucrisa and Taltz. The most notable of the four are Cosentyx and Otezla, which were approved in 2015 and 2014, respectively, and are forecast to generate $3.8 billion and $2.7 billion from the therapy area in 2023, respectively. The two most recently approved psoriasis treatments, Taltz and Eucrisa, are not expected to achieve the same level of commercial success as Cosentyx or Otezla because they are entering a market that is already saturated with entrenched competitors that have reduced the level of unmet need.

Dermatology therapy area is dominated by top 20 pharma companies. In 2016 the most commercially successful companies in the therapy area were Johnson & Johnson, AbbVie, Amgen, Novartis and Pfizer. Across the forecast period these companies will continue to generate high revenue, but the companies will all see their market shares change.

The report “Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis” provides an introduction to dermatology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In depth, this report provides the following:

  • Provides an overview of the dermatology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the dermatology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: atopic dermatitis, acne vulgaris and psoriasis.
  • Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape in dermatology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area composes a large proportion of each company’s pipeline portfolio and total revenues.

Companies mentioned in this report: Johnson & Johnson, AbbVie, Amgen, Novartis, Pfizer

Scope:

  • Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the largest growth in market share?
  • Which companies rely heavily on revenue derived from antibacterial drugs?
  • How will the market respond to recent approvals?
  • Will generics and biosimilars have a significant impact on the market over the forecast period?
  • What class of drugs dominate the market?
  • What molecular targets are most popular in the pipeline?
  • What are the commercial prospects for the most promising late-stage products?

Reasons to Buy:

  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the dermatology pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
  • This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Astellas Pharma
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.3.1 Atopic Dermatitis
2.3.2 Acne Vulgaris
2.3.3 Psoriasis
2.4 Co-morbidities and Complications
2.5 Diagnosis, Scales and Grading
2.5.1 Atopic Dermatitis
2.5.2 Acne Vulgaris
2.5.3 Psoriasis
2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
2.6.1 Atopic Dermatitis
2.6.2 Acne Vulgaris
2.6.3 Psoriasis
2.7 Treatment
2.7.1 Topical Corticosteroids
2.7.2 Calcineurin Inhibitors
2.7.3 Retinoids
2.7.4 Systemic Immunosuppressive Agents
2.7.5 Biologics
2.7.6 Antihistamines
2.7.7 Hormonal Therapy
2.7.8 Moisturizers

3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab) - AbbVie
3.3 Remicade (infliximab) - Johnson & Johnson
3.4 Enbrel (etanercept) - Amgen
3.5 Stelara (ustekinumab) - Johnson & Johnson
3.6 Neoral (cyclosporine) - Novartis
3.7 Protopic (tacrolimus) - Astellas Pharma
3.8 Cosentyx (Secukinumab) - Novartis
3.9 Dupixent (dupilumab) Sanofi and Regeneron
3.10 Taltz (ixekizumab) - Eli Lilly
3.11 Eucrisa (crisaborole) - Pfizer
3.12 Siliq (Brodalumab) - Valeant Pharmaceuticals
3.13 Elidel (pimecrolimus)
3.14 Elocon (mometasone furoate)
3.15 Differin (adapalene)
3.16 Metolate (methotrexate)
3.17 Clobex (clobetasol propionate)
3.18 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Molecule Types in the Pipeline
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Assessment of Key Pipeline Products
4.5 Conclusion

5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Tumor Necrosis Factor-Alpha
5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors
5.3.3 Calcineurin
5.3.4 Glucocorticoid Receptors
5.3.5 Phosphodiesterase

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Novartis - Will Revenue from Cosentyx Continue to Increase in the Forecast Period?
6.1.2 AbbVie - Will Humira’s Patent Expiry Lead to Loss of Market Leadership?
6.1.3 Johnson & Johnson - Guselkumab and Stelara Fail to Offset Revenue Lost from Remicade
6.1.4 Sanofi - High Revenue Growth from Dupixent Will See Sanofi’s Revenue from the Dermatology Therapy Area Increase
6.1.5 Pfizer - Approval of Eucrisa to Drive Growth in the Dermatology Therapy Area
6.1.6 Celgene - Otezla Expected to Achieve Blockbuster Status in the Therapy Area
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Figures for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Figures for Co-development Deals Valued Above $100m

8 Appendix
8.1 References
8.2 Table of Epidemiology Forecast
8.3 Figure of All Clinical Stage Psoriasis, Atopic dermatitis and Acne vulgaris Pipeline Products
8.4 Abbreviations
8.5 Disease List
8.6 Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Market Size and Revenue Forecasts
8.6.4 Pipeline Analysis
8.6.5 Competitive Landscape
8.7 Contact Us
8.8 Disclaimer

List of Tables
Table 1: Dermatology, Global, Classification of Atopic Dermatitis Severity and Impact on Quality of Life
Table 2: Dermatology, Global, European Dermatology Forum Acne Vulgaris Classification
Table 3: Dermatology, Global, Classification of Acne Vulgaris Severity
Table 4: Dermatology, Global, Classification of Psoriasis Severity
Table 5: Dermatology, Global, Epidemiology of Dermatological Disorders, 2016
Table 6: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Humira, 2017
Table 7: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Remicade, 2017
Table 8: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Enbrel, 2017
Table 9: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Stelara, 2017
Table 10: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Neoral, 2017
Table 11: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Protopic, 2017
Table 12: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Cosentyx, 2017
Table 13: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Dupixent, 2017
Table 14: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Taltz, 2017
Table 15: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Eucrisa, 2017
Table 16: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Siliq, 2017
Table 17: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elidel, 2015
Table 18: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elocon, 2015
Table 19: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Differin, 2015
Table 20: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Metolate, 2017
Table 21: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Clobex, 2017
Table 22: Dermatology Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023
Table 23: Dermatology, Global, Usage of Generics Across Key Indications, 2017
Table 24: Dermatology Therapeutics Market, Global, Forecast Revenue by Company, 2016-2023
Table 25: Epidemiology Patterns for Atopic Dermatitis, 2015-2022
Table 26: Epidemiology Patterns for Acne Vulgaris, 2015-2022
Table 27: Epidemiology Patterns for Psoriasis, 2015-2022
Table 28: Abbreviations

List of Figures
Figure 1: Epidemiology Patterns for Atopic Dermatitis (million), 2016-2023
Figure 2: Epidemiology Patterns for Acne Vulgaris (million), 2016-2023
Figure 3: Epidemiology Patterns for Psoriasis (million), 2016-2023
Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2017
Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006-2023
Figure 6: Dermatology Therapeutics Market, Global, Johnson & Johnson’s Annual Revenue for Remicade ($bn), 2006-2023
Figure 7: Dermatology Therapeutics Market, Global, Merck & Co.’s Annual Revenue for Remicade ($bn), 2010-2023
Figure 8: Dermatology Therapeutics Market, Global, Amgen’s Annual Revenue for Enbrel ($bn), 2006-2023
Figure 9: Dermatology Therapeutics Market, Global, Pfizer’s Annual Revenue for Enbrel ($bn), 2010-2023
Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2023
Figure 11: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006-2023
Figure 12: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006-2015
Figure 13: Dermatology Therapeutics Market, Global, Revenue Forecast for Cosentyx ($bn), 2016-2023
Figure 14: Dermatology Therapeutics Market, Global, Revenue Forecast for Dupilumab ($bn), 2017-2023
Figure 15: Dermatology Therapeutics Market, Global, Revenue Forecast for Taltz ($bn), 2017-2023
Figure 16: Dermatology Therapeutics Market, Global, Revenue Forecast for Taltz ($bn), 2016-2023
Figure 17: Dermatology Therapeutics Market, Global, Revenue Forecast for Eucrisa ($bn), 2016-2023
Figure 18: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016-2022
Figure 19: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
Figure 20: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2017
Figure 21: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2017
Figure 22: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2017
Figure 23: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2017
Figure 24: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2017
Figure 25: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2017
Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 29: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 30: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
Figure 31: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
Figure 32: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 33: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 34: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016
Figure 35: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 36: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 37: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 38: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
Figure 39: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 40: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 41: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 42: Dermatology Therapeutics Market, Global, Revenue Forecast for Risankizumab ($m), 2016-2022
Figure 43: Dermatology Therapeutics Market, Global, Revenue Forecast for Zorblisa ($m), 2017-2023
Figure 44: Dermatology Therapeutics Market, Global, Revenue Forecast for Olumacostat glasaretil ($m), 2019-2023
Figure 45: Dermatology Therapeutics Market, Global, Revenue Forecast for Guselkumab ($m), 2016-2022
Figure 46: Dermatology Global, Market Size ($bn), 2016-2023
Figure 47: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023
Figure 48: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2016-2023
Figure 49: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015-2022
Figure 50: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015-2022
Figure 51: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015-2022
Figure 52: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015-2023
Figure 53: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2016-2023
Figure 54: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023
Figure 55: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 56: Dermatology, Global, Revenues by Product Type, 2016-2023
Figure 57: Dermatology, Global, Novartis, Annual Revenue Forecast ($bn), 2016-2023
Figure 58: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2016-2023
Figure 59: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022
Figure 60: Dermatology, Global, Sanofi, Annual Revenue Forecast ($bn), 2015-2022
Figure 61: Dermatology, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022
Figure 62: Dermatology, Global, Celgene Annual Revenue Forecast ($bn), 2016-2023
Figure 63: Dermatology, Global, Companies by Type, 2017
Figure 64: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2017
Figure 65: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015-2022
Figure 66: Dermatology, Global, Licensing Deals, 2006-2017
Figure 67: Dermatology, Global, Licensing Deals by Indication, 2006-2017
Figure 68: Dermatology, Global, Licensing Deals, 2006-2017
Figure 69: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017
Figure 70: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 1)
Figure 71: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 2)
Figure 72: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 3)
Figure 73: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 4)
Figure 74: Dermatology, Global, Co-development Deals, 2006-2017
Figure 75: Dermatology, Global, Co-development Deals by Indication, 2006-2017
Figure 76: Dermatology, Global, Co-development Deals, 2006-2017
Figure 77: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
Figure 78: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 1)
Figure 79: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 2)
Figure 80: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 3)
Figure 81: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 4)
Figure 82: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part
Figure 83: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part
Figure 84: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part
Figure 85: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part
Figure 86: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part
Figure 87: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part
Figure 88: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie
  • Amgen
  • Astellas Pharma
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi and Regeneron
  • Valeant Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll